Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19Article Published on 2023-03-012023-07-09 Journal: Cardiology in the Young [Category] COVID19(2023년), [키워드] COVID-19 paediatric heart transplant. REGEN-COV [DOI] 10.1017/S1047951122002190 PMC 바로가기
Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal AntibodiesCase Reports Published on 2022-12-152023-07-10 Journal: Internal medicine (Tokyo, Japan) [Category] COVID19(2023년), [키워드] COVID-19 frequently relapsing/steroid-dependent nephrotic syndrome minimal change disease monoclonal antibody therapy REGEN-COV rituximab [DOI] 10.2169/internalmedicine.0241-22 PMC 바로가기 [Article Type] Case Reports
Timing of REGEN-COV administration and progression to severe COVID-19Article Published on 2022-11-012022-10-05 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adjusted odds ratio administration association calculated Clinical course clinical trial conducted confounders COVID-19 COVID-19 patient COVID-19 patients death decrease demonstrated dominant early administration epidemiological finding Epidemiology evaluate Evidence examined Hospitalization hospitals Japan Logistic regression analysis monoclonal antibody Patient progression proportion receive REGEN-COV Result risk severe COVID-19 severe disease severity symptom onset the timing therapy Timing of administration Trial variant [DOI] 10.1016/j.jiac.2022.07.002 [Article Type] Article
Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemicArticle Published on 2022-09-012022-10-05 Journal: American journal of obstetrics & gynecology MFM [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] administration Admission adverse events anaphylaxis Atlanta authorization benefit casirivimab and imdevimab Clinical course Clinical outcome Cohort cohort of patient COVID-19 COVID-19 illness COVID-19 pandemic COVID-19 therapeutics death drug Effect Efficacy eligible Emergency food groups high-risk population higher risk Hospital stay Hospitalization Hypothesis increased risk individual Infection instance intensive care less Maternal morbidity Memorial monoclonal antibodies monoclonal antibody morbidity and mortality need for oxygen Neonatal Neonatal morbidity no significant difference nonpregnant novel therapies offered outcome outcomes Oxygen requirement patients with SARS-CoV-2 pharmacologic treatment Placebo polymerase chain positive Pregnancy pregnant pregnant patient pregnant patients pregnant population receive reduce reduced REGEN-COV released resolved Respiratory illness retrospective cohort study risk Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 viral load severe COVID-19 severe disease Shortness of breath shown side statistically significant difference Symptom tested therapy thought treated Treatment treatment guideline Trial trials ventilatory support were excluded worsening [DOI] 10.1016/j.ajogmf.2022.100673 [Article Type] Article
Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders코로나바이러스 2019(COVID-19) 및 면역결핍 관련 항체 장애 환자에서 REGEN-COV®의 자비로운 사용Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 신약개발, 진단, [키워드] Adverse adverse events antibody Antibody deficiency B-cell B-cell deficiency Casirivimab Chain Reaction Clinical improvement clinical status compassionate use complications COVID-19 COVID-19 infection death Diagnosis disorder event higher risk Imdevimab immunodeficiency immunodeficient patient immunodeficient patients improvement infusion median time Medical conditions monoclonal antibody negative RT-PCR objective outcome oxygenation status Patient patients patients with COVID-19 polymerase chain reaction Quantitative REGEN-COV reported Retrospective analysis RT-PCR Serious Adverse Events subset Treatment viable treatment Viral viral clearance Viral load with COVID-19 [DOI] 10.1093/cid/ciab1059 PMC 바로가기 [Article Type] Article
Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes심각한 COVID-19 결과를 예방하는 REGEN-COV 항체 조합의 효과Article Published on 2022-08-022022-09-11 Journal: Nature Communications [Category] SARS, 변종, 임상, 진단, 치료법, [키워드] 95% CI antibody combination approved Casirivimab Clinical characteristics Combination COVID-19 COVID-19 hospitalization COVID-19 patients death defined delta variant demographic demographic and clinical characteristics determine Diagnosis effective Effectiveness Estimated FIVE hazard ratio healthcare high-risk patient High-risk patients Hospitalization Imdevimab infected with SARS-CoV-2 monoclonal antibodies monoclonal antibody outcome Patient performed reducing REGEN-COV Repository retrospective cohort study risk severe COVID-19 severe disease treated Treatment Treatment effectiveness used data were used [DOI] 10.1038/s41467-022-32253-9 PMC 바로가기 [Article Type] Article
Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan일본에서 SARS-CoV-2 양성 유지 투석 환자에서 카시리비맙/임데비맙 투여의 안전성Article Published on 2022-08-012022-09-12 Journal: CEN case reports [Category] SARS, 진단, [키워드] abnormal immune response Administered administration antibody cocktail approved Baricitinib casirivimab/imdevimab controlling coronavirus disease COVID-19 cytokine secretion dialysis Diseases Healthcare system Hemodialysis high risk Inflammation infusion Japan monoclonal antibody Neutralizing Patient patients with COVID-19 positive reaction receiving REGEN-COV Remdesivir Safe Safety SARS-CoV-2 severe disease supplemental oxygen therapeutic strategy therapy Treatment [DOI] 10.1007/s13730-021-00671-1 PMC 바로가기 [Article Type] Article
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fallArticle Published on 2022-06-012023-07-08 Journal: Expert opinion on drug discovery [Category] COVID19(2023년), [키워드] Casirivimab Imdevimab REGEN-COV REGN-CoV-2 Ronapreve [DOI] 10.1080/17460441.2022.2058486
Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis카시리비맙 및 임데비맙과 결합된 항체 칵테일 요법이 실제 환경에서 COVID-19 환자의 임상 결과에 미치는 영향: 단일 기관 분석Article Published on 2022-04-012022-09-12 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95%CI Analysis analyzed antibody cocktail Casirivimab clinical Clinical practice clinical trial cocktail Combined COVID-19 COVID-19 pandemic death effective Factor high-risk patient hospital Hospitalization Hospitalized Imdevimab Impact initial Isolation medical intervention oxygen saturation Patient patients with COVID-19 recent reduced reducing reduction REGEN-COV risk Ronapreve SARS-CoV-2 significantly therapy with COVID-19 [DOI] 10.1016/j.ijid.2022.01.067 PMC 바로가기 [Article Type] Article
Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort studySARS-CoV-2의 B.1.617.2(델타) 변이체에 대한 REGEN-COV 항체 칵테일의 효과: 코호트 연구Article Published on 2022-03-012022-09-11 Journal: Journal of internal medicine [Category] SARS, 변종, 진단, [키워드] Abstract antibody cocktail B.1.617.2 cohort study pulmonary medicine REGEN-COV SARS-CoV-2 treatments variant [DOI] 10.1111/joim.13408 PMC 바로가기 [Article Type] Article